Recursive Adaptation - Addiction Medicine and Policy

Home
CASPR.org
Archive
About
Addiction News Updates
Lilly studying GLP-1s, alcohol deaths double, AstaZeneca cuts their OUD drug
 • 
Nicholas Reville
How an addiction medicine doctor has used tirzepatide to transform his own life, and translate that experience to benefit his patients.
"Everything changed when I was prescribed tirzepatide in 2019."
 • 
Noah Davis
An Innovation Agenda for Addiction
from CASPR and Institute for Progress (IFP)
 • 
Nicholas Reville
 and 
Willy Chertman

November 2024

CASPR is funding a VA study on GLP-1s and opioid use in veterans
Our first collaboration with the Department of Veterans Affairs.
 • 
Nicholas Reville
Hiring: Intellectual Property Researcher
We are seeking a motivated Intellectual Property Researcher to join us on a part-time or contract basis.
 • 
Lindsay Holden
New study: GLP-1s reduce alcohol hospitalizations
Plus: Novo shortages, EMS refusal, CASPR news, and wonderful anecdotes.
 • 
Nicholas Reville
Hiring: Development Director
The Development Director will play a critical role in securing and growing funding sources to support CASPR’s mission.
 • 
Lindsay Holden
GLP-1s for Reducing Addiction: Everything you need to know
The science, medicine, patient experiences, provider experiences, policy, and more.
 • 
Nicholas Reville
1
10 charts about how and why we haven't solved addiction (and how we can)
Plus the GLP-1 breakthrough that can change our course.
 • 
Nicholas Reville
GRACE for AUD: proposing GLP-1-based alcohol treatment initiation in the ED
Immediate-access craving relief therapy can provide short-term risk reduction and a bridge to treatment.
 • 
Nicholas Reville
FDA standards for addiction medicine studies are discouraging the development of medications
A shift away from abstinence-only and other binary metrics is overdue.
 • 
Nicholas Reville

October 2024

© 2024 CASPR
Privacy ∙ Terms ∙ Collection notice
Start WritingGet the app
Substack is the home for great culture